Regulation of hepatocyte activator inhibitor-1 expression by androgen and oncogenic transformation in the prostate

American Journal of Pathology

Volumn 167, Issue 1, 2005, Pages 255-266

  Knudsen, Beatrice S ^a   Lucas, Jared M ^a   Fazli, Ladan ^d   Hawley, Sarah ^a   Falcon, Seth ^a   Coleman, Iisa M ^a   Martin, Dan B ^a   Xu, Chang ^a   True, Lawrence D ^b   Gleave, Martin E ^d   Nelson, Peter S ^a   Ayala, Gustavo E ^c  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; HEPATOCYTE ACTIVATOR INHIBITOR 1; PROSTATE SPECIFIC ANTIGEN; SCATTER FACTOR; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CARCINOGENESIS; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION;

EID: 21244454942     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)62970-7     Document Type: Article

References (49)

1. Shimomura T, Denda K, Kitamura A, Kawaguchi T, Kito M, Kondo J, Kagaya S, Qin L, Takata H, Miyazawa K, Kitamura N: Hepatocyte growth factor activator inhibitor, a novel Kunitz-type serine protease inhibitor. J Biol Chem 1997, 272:6370-6376
2. Lin CY, Anders J, Johnson M, Dickson RB: Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk. J Biol Chem 1999, 274:18237-18242
3. Kataoka H, Suganuma T, Shimomura T, Itoh H, Kitamura N, Nabeshima K, Koono M: Distribution of hepatocyte growth factor activator inhibitor type 1 (HAI-1) in human tissues. Cellular surface localization of HAI-1 in simple columnar epithelium and its modulated expression in injured and regenerative tissues. J Histochem Cytochem 1999, 47:673-682
4. Miyazawa K, Shimomura T, Kitamura A, Kondo J, Morimoto Y, Kitamura N: Molecular cloning and sequence analysis of the cDNA for a human serine protease responsible for activation of hepatocyte growth factor. Structural similarity of the protease precursor to blood coagulation factor XII. J Biol Chem 1993, 268:10024-10028
5. Takeuchi T, Shuman MA, Craik CS: Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological, processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc Natl Acad Sci USA 1999, 96:11054-11061
6. Lin CY, Anders J, Johnson M, Sang QA, Dickson RB: Molecular cloning of cDNA for matriptase, a matrix-degrading serine protease with trypsin-like activity. J Biol Chem 1999, 274:18231-18236
7. Benaud C, Dickson RB, Lin CY: Regulation of the activity of matriptase on epithelial cell surfaces by a blood-derived factor. Eur J Biochem 2001, 268:1439-1447
8. Lee SL, Dickson RB, Lin CY: Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem 2000, 275:36720-36725
9. Kataoka H, Shimomura T, Kawaguchi T, Hamasuna R, Itoh H, Kitamura N, Miyazawa K, Koono M: Hepatocyte growth factor activator inhibitor type 1 is a specific cell surface binding protein of hepatocyte growth factor activator (HGFA) and regulates HGFA activity in the pericellular microenvironment. J Biol Chem 2000, 275:40453-40462
10. Shimomura T, Denda K, Kawaguchi T, Matsumoto K, Miyazawa K, Kitamura N: Multiple sites of proteolytic cleavage to release soluble forms of hepatocyte growth factor activator inhibitor type 1 from a transmembrane form. J Biochem (Tokyo) 1999, 126:821-828
11. Martin DB, Gifford DR, Wright ME, Keller A, Yi E, Goodlett DR, Aebersold R, Nelson PS: Quantitative proteomic analysis of proteins released by neoplastic prostate epithelium. Cancer Res 2004, 64:347-355
12. Oberst M, Anders J, Xie B, Singh B, Ossandon M, Johnson M, Dickson RB, Lin CY: Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo. Am J Pathol 2001, 158:1301-1311
13. Klezovitch O, Chevillet J, Mirosevich J, Roberts RL, Matusik RJ, Vasioukhin V: Hepsin promotes prostate cancer progression and metastasis. Cancer Cell 2004, 6:185-195
14. Tanimoto H, Yan Y, Clarke J, Korourian S, Shigemasa K, Parmley TH, Parham GP, O'Brien TJ: Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer. Cancer Res 1997, 57:2884-2887
15. Naldini L, Tamagnone L, Vigna E, Sachs M, Hartmann G, Birchmeier W, Daikuhara Y, Tsubouchi H, Blasi F, Comoglio PM: Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J 1992, 11:4825-4833
16. Mars WM, Zarnegar R, Michalopoulos GK: Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA. Am J Pathol 1993, 143:949-958
17. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF: Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003, 4:915-925
18. Vande Woude GF, Jeffers M, Conner J, Alvord G, Tsarfaty I, Resau J: Met-HGF/SF: tumorigenesis, invasion and metastasis. Ciba Found Symp 1997, 212:112-154
19. Kataoka H, Miyata S, Uchinokura S, Itoh H: Roles of hepatocyte growth factor (HGF) activator and HGF activator inhibitor in the pericellular activation of HGF/scatter factor. Cancer Metastasis Rev 2003, 22:223-236
20. Kataoka H, Itoh H, Hamasuna R, Meng JY, Koono M: Pericellular activation of hepatocyte growth factor/scatter factor (HGF/SF) in cotorectal carcinomas: roles of HGF activator (HGFA) and HGFA inhibitor type 1 (HAI-1). Hum Cell 2001, 14:83-93
21. Itoh H, Kataoka H, Tomita M, Hamasuna R, Nawa Y, Kitamura N, Koono M: Upregulation of HGF activator inhibitor type 1 but not type 2 along with regeneration of intestinal mucosa. Am J Physiol 2000, 278:G635-G643
22. Kataoka H, Hamasuna R, Itoh H, Kitamura N, Koono M: Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma. Cancer Res 2000, 60:6148-6159
23. Oberst MD, Johnson MD, Dickson RB, Lin CY, Singh B, Stewart M, Williams A, al-Nafussi A, Smyth JF, Gabra H, Sellar GC: Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters. Clin Cancer Res 2002, 8: 1101-1107
24. Kang JY, Dolled-Filhart M, Ocal IT, Singh B, Lin CY, Dickson RB, Rimm DL, Camp RL: Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res 2003, 63:1101-1105
25. Parr C, Watkins G, Mansel RE, Jiang WG: The hepatocyte growth factor regulatory factors in human breast cancer. Clin Cancer Res 2004, 10:202-211
26. Parr C, Jiang WG: Expression of hepatocyte growth factor/scatter factor, its activator, inhibitors and the c-Met receptor in human cancer cells. Int J Oncol 2001, 19:857-863
27. Gmyrek GA, Walburg M, Webb CP, Yu HM, You X, Vaughan ED, Vande Woude GF, Knudsen BS: Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor. Am J Pathol 2001, 159:579-590
28. De Marzo AM, Fedor HH, Gage WR, Rubin MA: Inadequate formalin fixation decreases reliability of p27 immunohistochemical staining: probing optimal fixation time using high-density tissue microarrays. Hum Pathol 2002, 33:756-760
29. Rocchi P, So A, Kojima S, Signaevsky M, Beraldi E, Fazli L, Hurtado-Coll A, Yamanaka K, Gleave M: Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 2004, 64:6595-6602
30. Chen D, Adenekan B, Chen L, Vaughan ED, Gerald W, Feng Z, Knudsen BS: Syndecan-1 expression in locally invasive and metastatic prostate cancer. Urology 2004, 63:402-407
31. Nelson PS, Clegg N, Arnold H, Ferguson C, Bonham M, White J, Hood L, Lin B: The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci USA 2002 99:11890-11895
32. Tusher VG, Tibshirani R, Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001, 98:5116-5121
33. R Development Core TEAM (2004): R: A Language and Environment for Statisticai Computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0.
34. De Marzo AM, Meeker AK, Epstein JI, Coffey DS: Prostate stem cell compartments: expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells. Am J Pathol 1998, 153:911-919
35. van Leenders GJ, Gage WR, Hicks JL, van Balken B, Aalders TW, Schalken JA, De Marzo AM: Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy. Am J Pathol 2003, 162:1529-1537
36. Knudsen BS, Edlund M: Prostate cancer and the met hepatocyte growth factor receptor. Adv Cancer Res 2004, 91:31-67
37. Ruska KM, Sauvageot J, Epstein JI: Histology and cellular kinetics of prostatic atrophy. Am J Surg Pathol 1998, 22:1073-1077
38. van Leenders G, van Balken B, Aalders T, Hulsbergen-van de Kaa C, Ruiter D, Schalken J: Intermediate cells in normal and malignant prostate epithelium express c-MET: implications for prostate cancer invasion. Prostate 2002, 51:98-107
39. Liu AY, True LD: Characterization of prostate cell types by CD cell surface molecules. Am J Pathol 2002, 160:37-43
40. Durand MK, Bodker JS, Christensen A, Dupont DM, Hansen M, Jensen JK, Kjelgaard S, Mathiasen L, Pedersen KE, Skeldal S, Wind T, Andreasen PA: Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis. Thromb Haemost 2004, 91:438-449
41. Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, Washington MK, Neilson EG, Moses HL: TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithella. Science 2004, 303:848-851
42. Cunha GR: Growth factors as mediators of androgen action during male urogenital development. Prostate Suppl 1996, 6:22-25
43. Schmidt C, Bladt F, Goedecke S, Brinkmann V, Zschiesche W, Sharpe M, Gherardl E, Birchmeier C: Scatter factor/hepatocyte growth factor is essential for liver development. Nature 1995, 373:699-702
44. List K, Haudenschild CC, Szabo R, Chen W, Wahl SM, Swaim W, Engelholm LH, Behrendt N, Bugge TH: Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis. Oncogene 2002, 21:3765-3779
45. Birchmeier C, Gherardi E: Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol 1998, 8:404-410
46. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM: Delineation of prognostic biomarkers in prostate cancer. Nature 2001, 412:822-826
47. Kirchhofer D, Peek M, Lipari MT, Billeci K, Fan B, Moran P: Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-IB (HAI-1B) and HAI-2. FEBS Lett 2005, 579:1945-1950
48. Shia S, Stamos J, Kirchhofer D, Fan B, Wu J, Corpuz RT, Santell L, Lazarus RA, Eigenbrot C: Conformational lability in serine protease active sites: structures of hepatocyte growth factor activator (HGFA) alone and with the inhibitory domain from HGFA inhibitor-1B. J Mol Biol 2005, 346:1335-1349
49. Herter S, Piper DE, Aaron W, Gabriele T, Cutler G, Cao P, Bhatt AS Choe Y, Craik CS, Walker N, Meininger D, Hoey T, Austin RJ: Hepatocyte growth factor is a preferred in vitro substrate for human Hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers. Biochem J 2005 (in press)